Cover image for Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Medicines review protocol

Downloads

Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Medicines review protocol

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date: 
18 December 2019
Publication type: 
Procedure
Intended audience: 
General public
Description: 

The reviewers will use data sources specified in this document and results of stakeholder consultation to describe:

  • prevalence of mucopolysaccharidosis type VI (MPS VI) in Australia
  • management of MPS VI in comparison to Life Saving Drugs Program (LSDP) guidelines
  • clinical and comparative effectiveness and safety of medicines
  • relevant patient-based outcomes
  • value for money of LSDP treatment for MPS VI
  • use of the LSDP MPS VI medicines
  • developing technologies that may impact future access.